Unlisted Deals:
ador powertron 500.00 (4,900.00 %) amol minechem 601.00 (0.17 %) anglo french drugs 950.00 (2.15 %) anugraha valve 510.00 (0.99 %) apl metals 40.00 (-2.44 %) apollo fashion 92.00 (-4.17 %) arkfin investments 50.00 arohan 250.00 (-1.96 %) assam carbon 310.00 (-1.59 %) avalokiteshvar 242.00 (0.83 %) axles india 680.00 (0.74 %) balmer lawrie 200.00 (-0.99 %) bharat hotels 375.00 (-1.32 %) bima mandi 235.00 (-2.08 %) bira 545.00 (-0.91 %) blsx limited 35.00 (2.94 %) boat 1,550.00 (-1.90 %) c & s electric 1,070.00 (1.90 %) cable corporation 24.50 (2.08 %) capgemini 14,600.00 (-1.02 %) care health 185.00 (-1.60 %) carrier aircon 550.00 (0.92 %) cial 470.00 (-1.05 %) csk 198.00 (-0.50 %) dalmia refract 270.00 (-1.82 %) dfm foods 467.00 dsp merrill lynch 1,000.00 east india pharma 39.00 (-2.50 %) eaton fluid 445.00 (1.14 %) electronica plastic 4,500.00 (2.27 %) elgi ultra 400.00 elofic industries 2,850.00 (1.79 %) esl steel 42.00 (-2.33 %) fincare business 87.00 (1.16 %) fincare sfbl 205.00 (1.49 %) finopaytech limited 149.00 (-0.67 %) flipkart india 231,001.00 (0.00 %) frick india 3,500.00 (-1.41 %) gkn driveline 1,750.00 (2.94 %) goodluck defence 296.00 (-1.00 %) group pharma 300.00 gynofem healthcare 59.00 (-1.67 %) hazira cargo terminals limited 205.00 (1.49 %) hdb financial 1,210.00 (-1.22 %) hdfc ergo 370.00 (1.70 %) hdfc securities 11,300.00 (-2.59 %) hella india 900.00 (-2.17 %) hero fincorp 1,980.00 (-0.50 %) hexaware 985.00 (-0.51 %) hicks 1,600.00 (1.59 %) hira ferro 200.00 (2.56 %) honeywell electrical 7,200.00 (1.41 %) ikf finance 320.00 (-3.03 %) incred financial 10.00 (1.01 %) incred holdings 156.00 (-1.27 %) india carbon 1,120.00 (-1.32 %) india exposition 121.00 (0.83 %) indian potash 3,100.00 (-1.59 %) indian seamless 195.00 (2.63 %) indo alusys 25.75 (-0.96 %) indofil 1,430.00 (-0.69 %) infinite computer 405.00 (1.25 %) inkel 22.50 (-2.17 %) jana small finance bank 75.00 kel 575.00 (0.88 %) kial 137.00 (-0.72 %) klm axiva 15.50 (3.33 %) kurlon limited 1,275.00 (1.59 %) lava 45.00 (-2.17 %) mahindra rural mrhfl 100.00 manipal housing 74.00 (2.07 %) manjushree technopack 875.00 (0.57 %) martin & harris 820.00 (-1.20 %) matrix gas 810.00 (-2.41 %) merino 3,250.00 (-1.52 %) minosha 282.00 (0.71 %) mitsubishi heavy 207.00 (-0.48 %) mkcl 435.00 (1.16 %) mobikwik 640.00 (-1.54 %) mohan meakin 2,400.00 (2.13 %) mohfl 13.25 (-1.85 %) msei 1.80 (-2.70 %) msil 34.00 (3.03 %) nayara energy 690.00 (1.47 %) nayara energy ncd 320.00 (1.59 %) ncdex 200.00 (-0.99 %) ncl buildtek 310.00 (-3.13 %) ncl holdings 106.00 (0.95 %) nsdl 850.00 (3.03 %) nse india 1,850.00 (-2.63 %) onix renewable 16,000.00 (6.67 %) orbis financial 400.00 (-1.23 %) oswal minerals 60.10 (-1.48 %) otis elevator 4,100.00 (2.50 %) oyo rooms 53.00 (-1.85 %) panasonic appliances 262.00 (0.77 %) paymate india 500.00 (-1.96 %) pharmeasy 8.50 (3.03 %) pharmed limited 620.00 (0.81 %) philips domestic 675.00 (-1.46 %) philips india 925.00 (-0.54 %) pnb metlife 70.00 proyuga adtech 25.00 purity flexpack 20.00 ramaraju surgical 265.00 (1.92 %) rapido 16,650.00 (0.03 %) rasoi 82,000.00 (2.50 %) reliance gic 480.00 (-2.04 %) resins plastics 525.00 (-0.94 %) ring plus aqua 560.00 (1.82 %) rrp s4e innovation 300.00 (-3.23 %) sab miller 535.00 (0.94 %) sbi amc 2,650.00 (-1.12 %) sbi general insurance 621.00 (0.16 %) scottish assam 505.00 (1.00 %) shriram life 261.00 (0.38 %) sigachi laboratories 36.00 (-2.70 %) signify 1,325.00 (-1.85 %) smile microfinance 51.00 (-1.92 %) sterlite grid 5 275.00 (-3.51 %) sterlite power 590.00 (-1.67 %) studds 980.00 (3.16 %) svsml 315.00 (2.94 %) t stanes 800.00 (1.27 %) tata capital 900.00 (-1.10 %) trl krosaki 1,750.00 (-1.41 %) urban tots 64.00 (-1.54 %) utkarsh coreinvest 290.00 (-1.69 %) vikram solar 445.00 (-1.11 %) vivriti capital 1,040.00 (-0.95 %)
×
BUY
SELL

Group Pharmaceuticals Latest Annual Report, Balance Sheet and Financials

Group Pharmaceuticals Limited (Group Pharma) Return Comparision with Primex 40 Index

Periods 1 Week 1 Month 3 Months 6 Months 1 Year 3 Years All Time
Primex-40
Group Pharmaceuticals Limited

Group Pharmaceuticals Limited Balance Sheet (Amt. In Lakhs)

 

PARTICULARS  31 March 2022  31 March 2021
Equity & Liabilities    
Shareholders Funds    
Share Capital 253.68 253.68
Reserves and Surplus 4,178.35 3,695.43
Money Received Against Share Warrants 0.00 0.00
Share Application Money Pending Allotment 0.00 0.00
Non-Current Liabilities    
Long Term Borrowings 0.00 0.00
Deferred Tax Liabilities 0.00 0.00
Other Long Term Liabilities 0.00 0.00
Long Term Provisions 204.18 0.00
Current Liabilities    
Short Term Borrowings 213.02 92.00
Trade Payables 800.23 540.86
Other Current Liabilities 478.35 593.07
Short Term Provisions 53.41 0.00
Total Equity and Liabilities 6,181.22 5,175.04
     
Assets    
Non-Current Assets    
Fixed Assets    
Tangible Assets 1,534.89 1,635.54
Intangible Assets 7.31 8.18
Capital Work-in-Progress 11.67 0.00
Intangible Assets Under Development 0.00 0.00
Non-Current Investments 0.00 0.00
Deferred Tax Assets 19.49 11.78
Long Term Loans and Advances 142.68 119.62
Other Non-Current Assets 0.00 0.00
Current Assets    
Current Investments 0.00 0.00
Inventories 1,381.98 1,458.59
Trade Receivables 2,214.35 1,399.54
Cash and Cash Equivalents 554.78 239.45
Short Term Loans and Advances 292.96 269.54
Other Current Assets 21.11 32.80
Total Assets 6,181.22 5,175.04

Group Pharmaceuticals Limited Profit & Loss Statement (Amt. In Lakhs)

 

PARTICULARS  31 March 2022  31 March 2021
Revenue from operations 13,029.35 10,465.33
Other income 77.34 96.89
Total revenue 13,106.69 10,562.22
Cost of materials consumed 4,812.50 3,714.94
Purchases of stock in trade 1,342.32 954.48
Changes in inventory 110.57 99.31
Employee benefit expenses 3,521.77 3,063.55
Finance costs 34.24 65.89
Depreciation and amortization 205.65 222.20
Other expenses 2,410.60 1,952.09
Total expenses 12,445.66 10,089.53
Total revenue less total expenses 661.03 472.69
Prior period and exceptional items 0.00 0.00
Profit before extraordinary items 661.03 472.69
Extraordinary items 0.00 0.00
Profit before tax 661.03 472.69
Current tax expense 185.81 170.52
Deferred tax expense -7.70 -3.71
Profit from continuing operations 482.92 305.88
Profit from discontinuing operations (after tax) 0.00 0.00
Net profit/loss 482.92 305.88

Group Pharmaceuticals Limited Consolidated Cash Flow Statement (Amt. In Lakhs)

 

Particulars  31 March 2022  31 March 2021
Cash flows from used in operating activities     
Profit before extraordinary items and tax 661.03 472.69
Adjustments for reconcile profit (loss)     
Adjustments to profit (loss)     
Adjustments for finance costs 34.25 65.89
Adjustments for depreciation and amortisation expense 205.65 222.2
Other adjustments to reconcile profit (loss) 0 -0.68
Other adjustments for non-cash items 3.78 8.07
Total adjustments to profit (loss) 243.68 295.48
Adjustments for working capital     
Adjustments for decrease (increase) in inventories 76.62 103.98
Adjustments for decrease (increase) in trade receivables -818.6 67.75
Adjustments for decrease (increase) in other current assets -17.04 15.47
Adjustments for increase (decrease) in trade payables 259.36 -126.49
Adjustments for increase (decrease) in other current liabilities -14.38 6.49
Adjustments for provisions 157.24 86.68
Total adjustments for working capital -356.8 153.88
Total adjustments for reconcile profit (loss) -113.12 449.36
Net cash flows from (used in) operations 547.91 922.05
Income taxes paid (refund) 203.54 167.57
Net cash flows from (used in) operating activities before extraordinary items 344.37 754.48
Net cash flows from (used in) operating activities 344.37 754.48
Cash flows from/used in investing activities     
Proceeds from sales of tangible assets 4.45 6.53
Purchase of tangible assets 120.26 139.13
Other inflows (outflows) of cash -430.84 0.4
Net cash flows from (used in) investing activities before extraordinary items -546.65 -132.2
Net cash flows from (used in) investing activities -546.65 -132.2
Cash flows from/used in financing activities     
Proceeds from borrowings 185.02 -461.32
Repayments of borrowings 64 -50
Interest paid 34.24 65.89
Net cash flows from (used in) financing activities before extraordinary items 86.78 -477.21
Net cash flows from (used in) financing activities 86.78 -477.21
Net increase (decrease) in cash and cash equivalents before effect of exchange rate changes -115.5 145.07
Net increase (decrease) in cash and cash equivalents -115.5 145.07
Cash and cash equivalents cash flow statement at end of period 106.56 222.06

 

Here is a summary of the Cash Flow Statement for the years 2022 and 2021 broken down by activity wise in rupees:

 

Cash Flows from Operating Activities:

 

1. Net Cash Flows from Operating Activities:

   - In 2022, the net cash generated from operating activities was ₹344.37 lakhs, which is significantly lower than the previous year 's figure of ₹754.48 lakhs in 2021.

   - This decrease indicates a reduction in the cash generated from core business operations.

 

2. Adjustments for Reconciliation of Profit (Loss):

   - Various adjustments are made to reconcile the reported profit (loss) to the cash provided by operating activities.

   - These adjustments include finance costs, depreciation, amortization expenses, and other non-cash items, totaling ₹113.12 lakhs in 2022 and ₹449.36 lakhs in 2021.

 

3. Adjustments for Working Capital:

   - Adjustments are made for changes in working capital components like inventories, trade receivables, trade payables, and provisions.

   - In 2022, there was a net decrease in working capital adjustments of ₹356.8 lakhs, compared to an increase of ₹153.88 lakhs in 2021.

 

Cash Flows from Investing Activities:

 

4. Net Cash Flows from Investing Activities:

   - The net cash used in investing activities was -₹546.65 lakhs in 2022 and -₹132.2 lakhs in 2021.

   - This includes proceeds from sales of tangible assets, purchase of tangible assets, and other inflows/outflows of cash related to investments.

 

Cash Flows from Financing Activities:

 

5. Net Cash Flows from Financing Activities:

   - Financing activities include proceeds from borrowings, repayments of borrowings, and interest paid.

   - In 2022, there was a net cash inflow of ₹86.78 lakhs from financing activities, while in 2021, there was a net outflow of -₹477.21 lakhs.

 

Overall Cash Flow:

 

6. Net Increase (Decrease) in Cash and Cash Equivalents:

   - The net increase (decrease) in cash and cash equivalents before the effect of exchange rate changes was -₹115.5 lakhs in 2022 and ₹145.07 lakhs in 2021.

   - This indicates the change in the company 's cash position before considering the impact of exchange rate fluctuations.

 

7. Cash and Cash Equivalents at the End of the Period:

   - As of March 31, 2022, the cash and cash equivalents on the balance sheet were ₹106.56 lakhs, whereas in 2021, it was ₹222.06 lakhs.

 

Financial Ratios of Group Pharmaceuticals Limited: N/A

Dividend History of Group Pharmaceuticals Limited:

 

Particulars

2022

Dividend (final + interim) (In Rs.)

2

Group Pharmaceuticals Annual Report

Group Pharmaceuticals Limited Annual Report 2021-22

Download
Wealth Wisdom - WWIPL

Most Searched Unlisted & Pre IPO Companies Stocks in India

Support Megha Support Neha

Copyright © 2024 Wealth Wisdom India Private Limited. All Rights Reserved.
www.wwipl.com - v.2.0.0

News Alert